Biogen SVP to Present on Early Detection of Alzheimer's in Women

Boston, MA -- September 15 2026: Women's HealthX is pleased to announce that Sarah Kleinpeter, Senior Vice President of the Global Alzheimer's Disease and Dementia Franchise at Biogen, has officially joined the speaker faculty for this year's summit at the Encore Boston Harbor.

As technical healthcare project pipelines face increasing pressure to move from breakthrough research to sustainable market access, the validation of data architectures built to support early clinical detection has never been more important.

Sarah leads global commercial and medical franchise operations at Biogen, a world-class biotechnology titan at the absolute vanguard of neurodegenerative and cognitive health validation.

Successfully navigating these complex care standards requires organizations to move beyond traditional reporting approaches. It requires clinical operations leads to understand how to integrate continuous monitoring tools and real-world evidence (RWE) directly into existing Electronic Health Record (EHR) workflows.

At its core, Sarah's presentation will examine how building integrated health systems and data policies can enable earlier detection of cognitive decline in women, ensuring that therapeutic innovations translate seamlessly into everyday patient life.

As biopharma leaders look for new methods to de-risk their 2027 development timelines and comply with strict federal guidelines, platforms that demonstrate true data provenance and clear regulatory-grade evidence are becoming increasingly vital.

We are delighted to welcome Sarah Kleinpeter to the Women's HealthX faculty and look forward to showcasing Biogen's landmark case studies this December!